# Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

> **NCT01520805** · PHASE2 · WITHDRAWN · sponsor: **Cornerstone Pharmaceuticals**

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** CPI-613

## Key facts

- **NCT ID:** NCT01520805
- **Lead sponsor:** Cornerstone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520805, "Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01520805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*